|
1.
|
L GreillierP AstoulMesothelioma and
asbestos-related pleural
diseasesRespiration76115200810.1159/00012757718583923
|
|
2.
|
JC WagnerCA SleggsP MarchandDiffuse
pleural mesothelioma and asbestos exposure in the North Western
Cape ProvinceBr J Ind Med17260271196013782506
|
|
3.
|
P DumortierL CopluV de MaertelaerS EmriI
BarisP De VuystAssessment of environmental asbestos exposure in
Turkey by bronchoalveolar lavageAm J Respir Crit Care
Med15818151824199810.1164/ajrccm.158.6.97121199847273
|
|
4.
|
B BarisAU DemirV ShehuY KarakocaG
KisacikYI BarisEnvironmental fibrous zeolite (erionite) exposure
and malignant tumors other than mesotheliomaJ Environ Pathol
Toxicol Oncol1518318919969216804
|
|
5.
|
P RuffieR FeldS MinkinDiffuse malignant
mesothelioma of the pleura in Ontario and Quebec: a retrospective
study of 332 patientsJ Clin Oncol71157116819892666592
|
|
6.
|
HI PassK KrandaBK TemeckI FeuersteinSM
SteinbergSurgically debulked malignant pleural mesothelioma:
results and prognostic factorsAnn Surg
Oncol4215222199710.1007/BF023066139142382
|
|
7.
|
VW RuschS PiantadosiEC HolmesThe role of
extra-pleural pneumonectomy in malignant pleural mesothelioma. A
Lung Cancer Study Group trialJ Thorac Cardiovasc
Surg1021919912072706
|
|
8.
|
NJ VogelzangJJ RusthovenJ SymanowskiPhase
III study of pemetrexed in combination with cisplatin versus
cisplatin alone in patients with malignant pleural mesotheliomaJ
Clin Oncol2126362644200310.1200/JCO.2003.11.13612860938
|
|
9.
|
PA JanneML TaffaroR SalgiaBE
JohnsonInhibition of epidermal growth factor receptor signaling in
malignant pleural mesotheliomaCancer Res6252425247200212234991
|
|
10.
|
CL ArteagaEpidermal growth factor receptor
dependence in human tumors: more than just
expression?Oncologist7Suppl
43139200210.1634/theoncologist.7-suppl_4-3112202786
|
|
11.
|
J BrabenderKD DanenbergR MetzgerEpidermal
growth factor receptor and HER2-neu mRNA expression in non-small
cell lung cancer is correlated with survivalClin Cancer
Res718501855200111448895
|
|
12.
|
A DestroGL CeresoliM FalleniEGFR
overexpression in malignant pleural mesothelioma. An
immunohistochemical and molecular study with clinico-pathological
correlationsLung
Cancer51207215200610.1016/j.lungcan.2005.10.01616384623
|
|
13.
|
K OkudaH SasakiO KawanoEpidermal growth
factor receptor gene mutation, amplification and protein expression
in malignant pleural mesotheliomaJ Cancer Res Clin
Oncol13411051111200810.1007/s00432-008-0384-418392851
|
|
14.
|
LL GarlandC RankinDR GandaraPhase II study
of erlotinib in patients with malignant pleural mesothelioma: a
Southwest Oncology Group StudyJ Clin
Oncol2524062413200710.1200/JCO.2006.09.763417557954
|
|
15.
|
V AgarwalMJ LindL CawkwellTargeted
epidermal growth factor receptor therapy in malignant pleural
mesothelioma: where do we stand?Cancer Treat
Rev37533542201010.1016/j.ctrv.2010.11.004
|
|
16.
|
ES KimV HirshT MokGefitinib versus
docetaxel in previously treated non-small-cell lung cancer
(INTEREST): a randomised phase III
trialLancet37218091818200810.1016/S0140-6736(08)61758-419027483
|
|
17.
|
FA ShepherdJ Rodrigues PereiraT
CiuleanuErlotinib in previously treated non-small-cell lung cancerN
Engl J Med353123132200510.1056/NEJMoa05075316014882
|
|
18.
|
J AlbanellJ Codony-ServatF RojoActivated
extracellular signal-regulated kinases: association with epidermal
growth factor receptor/transforming growth factor alpha expression
in head and neck squamous carcinoma and inhibition by
anti-epidermal growth factor receptor treatmentsCancer
Res61650065102001
|
|
19.
|
NI GoldsteinM PrewettK ZuklysP RockwellJ
MendelsohnBiological efficacy of a chimeric antibody to the
epidermal growth factor receptor in a human tumor xenograft
modelClin Cancer Res11311131819959815926
|
|
20.
|
DJ JonkerCJ O’CallaghanCS
KarapetisCetuximab for the treatment of colorectal cancerN Engl J
Med35720402048200710.1056/NEJMoa07183418003960
|
|
21.
|
R GovindanRA KratzkeJE Herndon IIGefitinib
in patients with malignant mesothelioma: a phase II study by the
Cancer and Leukemia Group BClin Cancer
Res1123002304200510.1158/1078-0432.CCR-04-194015788680
|
|
22.
|
S LiKR SchmitzPD JeffreyJJ WiltziusP
KussieKM FergusonStructural basis for inhibition of the epidermal
growth factor receptor by cetuximabCancer
Cell7301311200510.1016/j.ccr.2005.03.00315837620
|
|
23.
|
JD SatoT KawamotoAD LeJ MendelsohnJ
PolikoffGH SatoBiological effects in vitro of monoclonal antibodies
to human epidermal growth factor receptorsMol Biol
Med151152919836094961
|
|
24.
|
GN GillT KawamotoC CochetMonoclonal
anti-epidermal growth factor receptor antibodies which are
inhibitors of epidermal growth factor binding and antagonists of
epidermal growth factor binding and antagonists of epidermal growth
factor-stimulated tyrosine protein kinase activityJ Biol
Chem259775577601984
|
|
25.
|
T KawamotoJD SatoA LeJ PolikoffGH SatoJ
MendelsohnGrowth stimulation of A431 cells by epidermal growth
factor: identification of high-affinity receptors for epidermal
growth factor by an anti-receptor monoclonal antibodyProc Natl Acad
Sci USA8013371341198310.1073/pnas.80.5.1337
|
|
26.
|
M NaramuraSD GilliesJ MendelsohnRA
ReisfeldBM MuellerTherapeutic potential of chimeric and murine
anti-(epidermal growth factor receptor) antibodies in a metastasis
model for human melanomaCancer Immunol
Immunother37343349199310.1007/BF015184588402738
|
|
27.
|
J KuraiH ChikumiK
HashimotoAntibody-dependent cellular cytotoxicity mediated by
cetuximab against lung cancer cell linesClin Cancer
Res1315521561200710.1158/1078-0432.CCR-06-172617332301
|
|
28.
|
H KimuraK SakaiT AraoT ShimoyamaT TamuraK
NishioAntibody-dependent cellular cytotoxicity of cetuximab against
tumor cells with wild-type or mutant epidermal growth factor
receptorCancer
Sci9812751280200710.1111/j.1349-7006.2007.00510.x17498200
|
|
29.
|
CS HenneyK KuribayashiDE KernS
GillisInterleukin-2 augments natural killer cell
activityNature291335338198110.1038/291335a06164929
|
|
30.
|
Z LiuFT LeeN HanaiCytokine enhancement of
in vitro antibody-dependent cellular cytotoxicity mediated by
chimeric anti-GD3 monoclonal antibody KM871Cancer
Immun213200212747758
|
|
31.
|
QH NguyenRL RobertsBJ AnkSJ LinCK LauER
StiehmEnhancement of antibody-dependent cellular cytotoxicity of
neonatal cells by interleukin-2 (IL-2) and IL-12Clin Diagn Lab
Immunol59810419989455889
|
|
32.
|
E NakatakiS YanoY MatsumoriNovel
orthotopic implantation model of human malignant pleural
mesothelioma (EHMES-10 cells) highly expressing vascular
endothelial growth factor and its receptorCancer
Sci97183191200610.1111/j.1349-7006.2006.00163.x
|
|
33.
|
GJ TodaroJE De LarcoGrowth factors
produced by sarcoma virus-transformed cellsCancer
Res38414741541978212188
|
|
34.
|
CJ WikstrandRE McLendonAH FriedmanDD
BignerCell surface localization and density of the tumor-associated
variant of the epidermal growth factor receptor, EGFRvIIICancer
Res574130414019979307304
|
|
35.
|
G BrockhoffF HofstaedterR KnuechelFlow
cytometric detection and quantitation of the epidermal growth
factor receptor in comparison to Scatchard analysis in human
bladder carcinoma cell
linesCytometry177583199410.1002/cyto.9901701108001460
|
|
36.
|
K DorshkindSB PollackMJ BosmaRA
PhillipsNatural killer (NK) cells are present in mice with severe
combined immunodeficiency (scid)J Immunol1343798380119853989296
|
|
37.
|
FR LuoZ YangH DongCorrelation of
pharmacokinetics with the antitumor activity of Cetuximab in nude
mice bearing the GEO human colon carcinoma xenograftCancer
Chemother
Pharmacol56455464200510.1007/s00280-005-1022-315947929
|
|
38.
|
R NiwaM SakuradaY KobayashiEnhanced
natural killer cell binding and activation by low-fucose IgG1
antibody results in potent antibody-dependent cellular cytotoxicity
induction at lower antigen densityClin Cancer
Res1123272336200510.1158/1078-0432.CCR-04-2263
|
|
39.
|
N PrangS PreithnerK BrischweinCellular and
complement-dependent cytotoxicity of Ep-CAM-specific monoclonal
antibody MT201 against breast cancer cell linesBr J
Cancer92342349200515655555
|
|
40.
|
A RalletMJ FarouxS TheobaldEpidermal
growth factor receptors in breast cancer: comparison of radioligand
and immunocytochemical assaysAnticancer
Res141417142119948067716
|
|
41.
|
JG KlijnPM BernsPI SchmitzJA FoekensThe
clinical significance of epidermal growth factor receptor (EGF-R)
in human breast cancer: a review on 5232 patientsEndocr
Rev1331719921313356
|
|
42.
|
R KimmigD PfeifferH LandsmannH
HeppQuantitative determination of the epidermal growth factor
receptor in cervical cancer and normal cervical epithelium by
2-color flow cytometry: evidence for down-regulation in cervical
cancerInt J
Cancer74365373199710.1002/(SICI)1097-0215(19970822)74:4%3C365::AID-IJC1%3E3.0.CO;2-T
|
|
43.
|
KA SmithInterleukin-2: inception, impact,
and
implicationsScience24011691176198810.1126/science.31318763131876
|
|
44.
|
E HooijbergJJ SeinPC van den
BerkEradication of large human B cell tumors in nude mice with
unconjugated CD20 monoclonal antibodies and interleukin 2Cancer
Res552627263419957540106
|
|
45.
|
J GolayM ManganiniV
FacchinettiRituximab-mediated antibody-dependent cellular
cytotoxicity against neoplastic B cells is stimulated strongly by
interleukin-2Haematologica8810021012200312969808
|
|
46.
|
M KuboT MorisakiH KurokiCombination of
adoptive immunotherapy with Herceptin for patients with
HER2-expressing breast cancerAnticancer
Res2344434449200314666732
|
|
47.
|
WE CarsonR PariharMJ
LindemannInterleukin-2 enhances the natural killer cell response to
Herceptin-coated Her2/neu-positive breast cancer cellsEur J
Immunol3130163025200110.1002/1521-4141(2001010)31:10%3C3016::AID-IMMU3016%3E3.0.CO;2-J11592078
|
|
48.
|
K KonoA TakahashiF IchiharaH SugaiH FujiiY
MatsumotoImpaired antibody-dependent cellular cytotoxicity mediated
by herceptin in patients with gastric cancerCancer
Res6258135817200212384543
|
|
49.
|
AD SantinS BelloneM GokdenOverexpression
of HER-2/neu in uterine serous papillary cancerClin Cancer
Res812711279200212006548
|
|
50.
|
N BerinsteinR LevyTreatment of a murine B
cell lymphoma with monoclonal antibodies and IL-2J
Immunol13997197619873496394
|
|
51.
|
WM VuistF v BuitenenMA de RieA HekmanP
RumkeCJ MeliefPotentiation by interleukin 2 of Burkitt’s lymphoma
therapy with anti-pan B (anti-CD19) monoclonal antibodies in a
mouse xenotransplantation modelCancer Res49378337881989
|
|
52.
|
WL GluckD HurstA YuenPhase I studies of
interleukin (IL)-2 and rituximab in B-cell non-Hodgkin’s lymphoma:
IL-2 mediated natural killer cell expansion correlations with
clinical responseClin Cancer Res10225322642004
|
|
53.
|
GF FlemingNJ MeropolGL RosnerA phase I
trial of escalating doses of trastuzumab combined with daily
subcutaneous interleukin 2: report of cancer and leukemia group B
9661Clin Cancer Res837183727200212473581
|
|
54.
|
T RepkaEG ChioreanJ GayTrastuzumab and
inter-leukin-2 in HER2-positive metastatic breast cancer: a pilot
studyClin Cancer Res924402446200312855616
|
|
55.
|
M SuzukiM Kato-NakanoS KawamotoTherapeutic
antitumor efficacy of monoclonal antibody against Claudin-4 for
pancreatic and ovarian cancersCancer
Sci10016231630200910.1111/j.1349-7006.2009.01239.x19555390
|
|
56.
|
DE Lopes de MenezesK Denis-MizeY
TangRecombinant interleukin-2 significantly augments activity of
rituximab in human tumor xenograft models of B-cell non-Hodgkin
lymphomaJ Immunother306474200717198084
|
|
57.
|
JM RodaT JoshiJP ButcharThe activation of
natural killer cell effector functions by cetuximab-coated,
epidermal growth factor receptor positive tumor cells is enhanced
by cytokinesClin Cancer
Res1364196428200710.1158/1078-0432.CCR-07-086517962339
|
|
58.
|
T AzizA JilaihawiD PrakashThe management
of malignant pleural mesothelioma; single centre experience in 10
yearsEur J Cardiothorac Surg22298305200212142203
|
|
59.
|
O MonneuseAC BeaujardB GuibertLong-term
results of intrathoracic chemohyperthermia (ITCH) for the treatment
of pleural malignanciesBr J
Cancer8818391843200310.1038/sj.bjc.660100012799624
|
|
60.
|
H SchouwinkET RutgersJ van der
SijpIntraoperative photodynamic therapy after pleuropneumonectomy
in patients with malignant pleural mesothelioma: dose finding and
toxicity resultsChest12011671174200110.1378/chest.120.4.1167
|
|
61.
|
W Den OtterJJ JacobsJJ BattermannLocal
therapy of cancer with free IL-2Cancer Immunol
Immunother57931950200818256831
|
|
62.
|
B CastagnetoS ZaiL MuttiPalliative and
therapeutic activity of IL-2 immunotherapy in unresectable
malignant pleural mesothelioma with pleural effusion: results of a
phase II study on 31 consecutive patientsLung
Cancer31303310200110.1016/S0169-5002(00)00192-6
|
